Abiomed Hits TCT 2019 Running with Compelling Data and New Approval

Abiomed certainly brought its A-game to the 31st annual Transcatheter Cardiovascular Therapeutics (TCT) conference- being held now and throughout the weekend. The Danvers, MA-based company came armed with the news of a newly-approved device and data from its PROTECT III trial, an ongoing prospective, single-arm FDA post-market study for the Impella 2.5 and Impella CP in high-risk PCI.